Welcome to our dedicated page for Avanos Medical SEC filings (Ticker: AVNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avanos Medical, Inc. filings document the regulatory record of a medical technology company with product portfolios in Specialty Nutrition Systems and Pain Management and Recovery. Current reports furnish operating results, segment performance, investor presentations, material definitive agreements, executive compensation actions and organizational restructuring disclosures.
Proxy materials describe annual meeting matters, board elections, governance practices and compensation programs. The filings also cover capital-structure disclosures, shareholder voting matters, product-portfolio descriptions for enteral feeding and non-opioid pain therapies, and formal exhibits tied to material events.
Avanos Medical, Inc. principal accounting officer John Joseph Hurley reported equity award activity in company common stock. On March 6, 2026, 919 performance-based restricted share units vested, resulting in the acquisition of 919 shares at $13.79 per share through an exercise of derivative securities.
On the same date, Hurley surrendered 321, 144, and 211 shares of common stock to the issuer to satisfy tax withholding obligations tied to the vesting of the 919 performance-based RSUs and time-based RSUs of 413 and 604 units. After these transactions, he directly owned 11,607 shares of Avanos common stock.
AVANOS MEDICAL, INC. SVP and Chief Financial Officer Scott Michael Galovan reported equity award activity in company stock. On March 6, 2026, he acquired 5,907 shares of common stock at $13.79 per share through the vesting of performance-based restricted share units.
On the same date, he disposed of multiple blocks of common stock at $13.79 per share to satisfy tax withholding obligations tied to the vesting of performance-based and time-based restricted share units, rather than through open-market sales. After these transactions, he directly owned 111,462 shares of Avanos common stock.
Avanos Medical entered into a cooperation agreement with investor Bradley L. Radoff and The Radoff Family Foundation. The Board agreed to nominate James L. Cunniff and a second independent director for election at the 2026 annual meeting, and to appoint Mr. Cunniff to at least one Board committee after that meeting.
In return, Mr. Radoff withdrew his director nomination and the Radoff Parties accepted standstill and voting commitments lasting until a defined period ahead of the 2027 annual meeting. Avanos also announced it intends to nominate William P. Burke as the second independent director. Full details will appear in the company’s future proxy materials.
Avanos Medical, Inc. files its annual report describing a focused medical technology business built around two segments: Specialty Nutrition Systems and Pain Management & Recovery. Key brands include MIC-KEY, Corpak, NeoMed, ON-Q, COOLIEF and newly added Nexus vascular access products.
In 2025 Avanos acquired Nexus Medical for $27.0 million plus up to $20.0 million in contingent consideration and highlights the earlier $53.0 million Diros RFA acquisition and the $110.0 million sale of its Respiratory Health business. The company is executing a multi‑year transformation with portfolio divestitures, cost actions and organizational changes, while disclosing significant goodwill impairments of $77.0 million in 2025 and $336.5 million in 2024. Avanos emphasizes heavy regulation, reimbursement pressure, supply‑chain and tariff exposure from its manufacturing concentration in Mexico, and outlines broad operational, financial, cybersecurity, AI and geopolitical risks. It reports 2,287 employees worldwide, R&D investment of $23.3 million in 2025 and diversity and engagement initiatives supporting its global workforce.
Avanos Medical reported modest growth for 2025 with net sales rising 1.9% to $701.2 million, driven mainly by a 9.2% increase in Specialty Nutrition Systems revenue to $432.9 million. Pain Management and Recovery sales grew 1.5% to $237.8 million.
The company posted a 2025 net loss of $72.9 million, a substantial improvement from a $392.1 million loss in 2024, though this year included a non-cash goodwill impairment of $77.0 million in the PM&R segment. On an adjusted basis, operating profit declined to $67.1 million and adjusted EBITDA fell to $86.8 million from $107.6 million, while adjusted diluted EPS decreased to $0.94 from $1.35.
Free cash flow for 2025 dropped to $43.1 million from $82.9 million, but net debt improved to $10.7 million as of December 31, 2025. For 2026, Avanos expects net sales between $700 million and $720 million and adjusted diluted EPS between $0.90 and $1.10, while transformation initiatives are targeted to deliver $15–$20 million of incremental annualized savings by the end of 2026.
Avanos Medical, Inc. ownership update: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 3,200,000 shares, representing 5.39% of common stock.
The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and that Mr. Boyd, as managing member, may be deemed to beneficially own the shares. The Master Fund is identified as the holder entitled to dividend or sale proceeds.
Avanos Medical, Inc. received an updated ownership report showing that Robert G. Moses Capital, LLC now reports beneficial ownership of 0 shares of Avanos common stock, representing 0.0% of the outstanding class as of 12/31/2025.
The filer confirms it owns 5 percent or less of the stock class and has no sole or shared power to vote or dispose of any shares. It also certifies that any securities referenced were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Avanos Medical.
Dimensional Fund Advisors LP filed an amended Schedule 13G reporting its beneficial ownership of Avanos Medical Inc common stock. Dimensional reports beneficial ownership of 2,157,531 shares of Avanos Medical, representing 4.6% of the outstanding common stock as of the event date 12/31/2025. It reports sole power to vote 2,087,813 shares and sole power to dispose of 2,157,531 shares, with no shared voting or dispositive power.
The shares are owned by various funds and accounts advised or managed by Dimensional or its subsidiaries, and Dimensional states that it may be deemed a beneficial owner because it has voting and/or investment power. Dimensional disclaims beneficial ownership of these securities and indicates that each underlying fund’s interest is below 5% of the class. The filing also certifies that the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Avanos Medical.
Avanos Medical, Inc. filed a current report describing an investor presentation being given at the JP Morgan Healthcare Conference. On January 13, 2026, the company will present and discuss a slide deck that is included as Exhibit 99.1 to this report and incorporated by reference for informational purposes.
The company clarifies that the materials furnished under Regulation FD are not considered “filed” under the Securities Exchange Act and are not subject to related liability provisions. These materials will also not be automatically incorporated into any securities registration statements or other documents unless specifically stated in those future filings.
Avanos Medical filed an amended report to clarify severance terms for two departing executives as part of a broader organizational restructuring. The company eliminated the roles of Chief Commercial Officer and General Counsel, notifying Kerr Holbrook and Mojirade James that their employment would end effective December 1, 2025, with their responsibilities reassigned to other employees.
Under the Severance Pay Plan, Avanos will pay Mr. Holbrook $1,535,417 and Ms. James $1,425,665 in cash severance and cover 100% of their COBRA premiums for 12 months. Time-based restricted stock units for both executives vested pro rata on December 1, 2025, while performance-based awards will vest based on actual performance. The amendment specifies that all 16,300 time-based restricted stock units granted to Ms. James on April 22, 2025 vested in full on that date, and their stock options remain exercisable for up to five years, subject to standard conditions and release agreements.